University College Dublin, through NovaUCD and ConsultUCD, has received five nominations for this year’s Knowledge Transfer Ireland (KTI) Impact Awards.
UCD and Glanbia have been shortlisted for the Collaborative Research Impact Award for the AgriChemWhey project. This project is focused on the transformation of dairy waste products into high-value, bio-based products for global markets.
UCD and Atlantic Therapeutics are nominated for the Licence2Market Impact Award. Atlantic Therapeutics, headquartered in Galway, develops professional and consumer medical devices to treat all types of incontinence and other associated disorders.
Equal1 Labs, headquartered at NovaUCD with a base in the US, got on the shortlist for the Spin-out Company Award. Equal1 Labs is the world’s first quantum computing hardware start-up developing a new type of quantum computer.
ConsultUCD is shortlisted for the Consultancy Impact Award for a study carried out by UCD academics on Toyota’s hybrid powertrain system. The study was commissioned by Toyota Ireland through ConsultUCD, to examine the performance of the cars in typical Irish commuting conditions.
Lastly Simon Factor, NovaUCD’s Senior Manager for New Ventures, has been shortlisted for the Knowledge Transfer Achiever of the Year Award.
Tom Flanagan, UCD Director of Enterprise and Commercialisation was delighted with UCD’s nominations. “This indicates the strength, breadth and quality of the knowledge transfer and consultancy activities being undertaken by UCD researchers with the guidance and support of the NovaUCD technology transfer and ConsultUCD teams.”
Winners of the 2019 KTI Impact Awards will be announced at an awards ceremony which will be held on 21 November in The Alex Hotel, Dublin 2.
The full 2019 KTI Impact Awards shortlist is available via https://www.knowledgetransferireland.com/Events/KTI-Impact-Awards/KTI-Impact-Awards-2019/
